Indication
In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Medicine details

Medicine name:
daratumumab (Darzalex)
SMC ID:
SMC2180
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Submission type
Full
Status
Publication due date:
08 July 2019
SMC meeting date:
04 June 2019
Patient group submission deadline:
01 April 2019